RxSight, Inc.
Income Statement
| Line Item | Jul 2025 | Jun 2025 | Apr 2025 | Mar 2025 | Feb 2025 | Dec 2024 | Oct 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $33.6M | — | $37.9M | — | — | — | $35.3M |
| Cost of Revenue | — | $8.4M | — | $9.6M | — | — | — | $10.1M |
| Gross Profit | — | $25.2M | — | $28.3M | — | — | — | $25.2M |
| Gross Margin | — | 74.9% | — | 74.8% | — | — | — | 71.4% |
| Operating Expenses | ||||||||
| Research & Development | — | $10.2M | — | $10.4M | — | — | — | $8.8M |
| SG&A Expense | — | $29.0M | — | $28.6M | — | — | — | $25.6M |
| Operating Income | — | $-14.0M | — | $-10.7M | — | — | — | $-9.2M |
| Operating Margin | — | -41.6% | — | -28.2% | — | — | — | -26.1% |
| Interest Expense | — | $5.0K | — | $6.0K | — | — | — | $5.0K |
| Pretax Income | — | $-11.8M | — | $-8.2M | — | — | — | $-6.3M |
| Income Tax Expense | — | $32.0K | — | $18.0K | — | — | — | $13.0K |
| Net Income | — | $-11.8M | — | $-8.2M | — | — | — | $-6.3M |
| Net Margin | — | -35.0% | — | -21.6% | — | — | — | -17.9% |
| EPS (Basic) | — | $-0.29 | — | $-0.20 | — | — | — | $-0.16 |
| EPS (Diluted) | — | $-0.29 | — | $-0.20 | — | — | — | $-0.16 |
| Shares Outstanding (Basic) | 40.9M | 40.7M | 40.6M | 40.5M | 40.5M | 40.4M | 40.3M | 39.8M |
| Shares Outstanding (Diluted) | 40.9M | 40.7M | 40.6M | 40.5M | 40.5M | 40.4M | 40.3M | 39.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |